Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer.

ABSTRACT:

Background

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have become the gold standard for EGFR-mutated non-small cell lung cancer (NSCLC) treatment. Immune checkpoint inhibitors (ICIs) have been developed for the treatment of several malignancies, including lung cancer. However, it is known that ICIs have poorer efficacy in EGFR-mutated NSCLC.

Methods

We collected data for patients with EGFR-mutated NSCLC receiving monotherapy with ICIs after EGFR-TKIs between December 2015 and March 2020 in three institutions, and retrospectively analyzed the association between patient characteristics and efficacy of ICIs.

Results

A total of 25 patients were included in this study. We defined responders as patients undergoing 90 days or longer of ICI treat

SUBMITTER: Ito T 

PROVIDER: S-EPMC8807326 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature